Nature 618, S19 (2023)
ISSN 1476-4687 (online) ISSN 0028-0836 (print)
Japanese translation site
Malaria stands as one of the three major global infectious diseases, alongside AIDS and tuberculosis. It predominantly affects tropical and subtropical regions, and individuals are infected through bites from mosquitoes (of the genus Anopheles) carrying the malaria parasite. Worldwide, there are an estimated 250 million infections annually, with reported deaths numbering around 620,000. The disease poses a grave global threat due to the insufficient efficacy of available preventive vaccines and the rising presence of parasites resistant to current treatments.
SHIONOGI has previously entered into collaborative agreements with Nagasaki University, jointly advancing research on the prevention and treatment of malaria. Nagasaki University has been a forerunner in infectious disease research since 1942, now boasting an unparalleled volume and quality of research in Japan. As a result, since the onset of 2023 alone, they have announced various initiatives and achievements in the research of malaria treatments.
1. Shionogi & Co., Ltd. signs a collaborative research agreement with MMV on the creation of new malaria treatment drugs. Additionally, selection by the GHIT Fund has been announced. (March 13, 2023)
2. Discovery of the synchronization mechanism between the malaria parasite and human circadian rhythm. - Hopes for the development of a new antimalarial drug that inhibits the molecular mechanism of onset - (July 6, 2023)
3. A genetically engineered Plasmodium falciparum expressing NanoLuc as an innovative tool for malaria drug discovery. (July 21, 2023)
4. First in the world to demonstrate in a mouse model the use of nanoparticles for an mRNA (Messenger RNA) vaccine. Successfully prevents the proliferation of parasites in the liver during the early stages of malaria infection. - Anticipations for the practical application of a malaria vaccine where cellular immunity takes the lead - (September 20, 2023)